Stay updated with breaking news from Nasdaq Drrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jonestrading reaffirmed their hold rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. Jonestrading currently has a $37.00 price objective on the specialty pharmaceutical company’s stock. A number of other equities research analysts have also recently weighed in on the company. Northland Securities assumed […]
Jonestrading restated their hold rating on shares of DURECT (NASDAQ:DRRX – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. Jonestrading currently has a $37.00 price objective on the specialty pharmaceutical company’s stock. A number of other brokerages also recently issued reports on DRRX. HC Wainwright downgraded DURECT from a […]
DURECT Co. (NASDAQ:DRRX – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,170,000 shares, a growth of 19.2% from the August 15th total of 1,820,000 shares. Currently, 8.0% of the shares of the company are sold […]
StockNews.com lowered shares of DURECT (NASDAQ:DRRX – Free Report) from a hold rating to a sell rating in a report issued on Saturday. Other research analysts have also recently issued reports about the company. Cantor Fitzgerald cut their price objective on DURECT from $44.00 to $41.00 and set an overweight rating for the company in […]
StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX – Free Report) in a research note issued to investors on Friday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald dropped their price objective on shares of DURECT from $44.00 […]